The regional administrative court (TAR Lombardia) ascertained the legitimacy of Bio-Rad Laboratories' award of the tender procedure launched by Fondazione IRCCS Istituto Nazionale dei Tumori with 15 other important hospital members of the consortium in Lombardy. The subject of the tender was the supply of medical devices aimed at immunohematology studies, with a value higher than EUR 1,200,000.

In particular, the court ascertained that the Lombardy Hospital, which specializes in the treatment of cancer, had correctly excluded Ortho-Clinical Diagnostic Italy S.r.l. from the tender procedure for violating the principle of the uniqueness of the offer pursuant to Article 32, para. 4 of Legislative Decree n. 50 dated 18 April 2016.

The victory represents a significant step forward for Bio-Rad Laboratories, a US multinational listed on NYSE, which gains credit as a leading company in the Italian market in supplying medical technologies for the immunohematology sector.

Pierfrancesco Federici (partner) and Francesco Goisis (of counsel) from the Milan office assisted Bio-Rad Laboratories.

Explore Our Newsroom